AzTrials
AzTrials

Acute Gouty ArthritisPhase 3NCT01356602

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

A Phase 3 study testing Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide in people with Acute Gouty Arthritis, run by Novartis Pharmaceuticals at 99 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Acute Gouty Arthritis
What is being tested?
Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
397 participants
Where
99 sitesin 5 countries
Study dates
May 2011to Sep 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 3 or more gout flares within last year
  • Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine
  • Body mass index of less than or equal to 45 kg/m2

Who cannot join

  • Use of the following therapies (within varying protocol defined timeframes): corticosteroids, narcotics, topical ice/cold packs, chronic opiate treatment, NSAIDs (such as aspirin), colchicine.
  • Hemodialysis
  • Live vaccine within 3 months before first dose
  • Donation or loss of 400 mL or more within 3 months before first dose
  • Gout brought on by other factors such as chemotherapy, lead, transplant, etc.
  • Presence of other acute inflammatory arthritis such as Rheumatoid Arthritis
Show all 12Show fewer
  • Any conditions or significant medical problems that puts the patient at an unacceptable immunological risk to receive this type of therapy such as HIV, Hepatitis, Tuberculosis and other infections/conditions
  • Significant cardiovascular conditions such as uncontrolled hypertension
  • Significant medical diseases such as uncontrolled diabetes, thyroid disease
  • History of malignancy of any organ system within the past 5 years
  • Women who are pregnant or nursing
  • Other protocol-defined inclusion/exclusion criteria may apply

Trial locations and contacts

99 sites in 5 countries.

99 sites in 5 countries

United States69 sites
  • Novartis Investigative Site

    Anniston, Alabama, 36207-5710

  • Novartis Investigative Site

    Asheville, North Carolina, 28801

  • Novartis Investigative Site

    Augusta, Georgia, 30904

  • Novartis Investigative Site

    Bedford, Texas, 76021

  • Novartis Investigative Site

    Bellevue, Washington, 98004

  • Novartis Investigative Site

    Belzoni, Mississippi, 39038

  • Novartis Investigative Site

    Bountiful, Utah, 84010

  • Novartis Investigative Site

    Bristol, Tennessee, 37620

  • Novartis Investigative Site

    Buena Park, California, 90620

  • Novartis Investigative Site

    Cary, North Carolina, 27518

  • Novartis Investigative Site

    Chandler, Arizona, 85224

  • Novartis Investigative Site

    Charleston, South Carolina, 29412

  • Novartis Investigative Site

    Charlotte, North Carolina, 28209

  • Novartis Investigative Site

    Charlotte, North Carolina, 28277

  • Novartis Investigative Site

    Charlottesville, Virginia, 22911

  • Novartis Investigative Site

    Clearwater, Florida, 33756

  • Novartis Investigative Site

    Columbia, South Carolina, 29204

  • Novartis Investigative Site

    Dallas, Texas, 75231

  • Novartis Investigative Site

    Danville, Virginia, 24541

  • Novartis Investigative Site

    Decatur, Georgia, 30035

  • Novartis Investigative Site

    Duncansville, Pennsylvania, 16635

  • Novartis Investigative Site

    Fair Oaks, California, 95628

  • Novartis Investigative Site

    Fargo, North Dakota, 58103

  • Novartis Investigative Site

    Fayetteville, Tennessee, 33734

  • Novartis Investigative Site

    Freehold, New Jersey, 07728

  • Novartis Investigative Site

    Greensboro, North Carolina, 27401

  • Novartis Investigative Site

    Greensboro, North Carolina, 27408

  • Novartis Investigative Site

    Greer, South Carolina, 29651

  • Novartis Investigative Site

    Gulf Shores, Alabama, 36547

  • Novartis Investigative Site

    Houston, Texas, 77034

  • Novartis Investigative Site

    Jackson, Mississippi, 39202

  • Novartis Investigative Site

    Jackson, Mississippi, 39209

  • Novartis Investigative Site

    Johnson City, Tennessee, 37601

  • Novartis Investigative Site

    Jupiter, Florida, 33458

  • Novartis Investigative Site

    Largo, Florida, 33773

  • Novartis Investigative Site

    Lincoln, Nebraska, 68516

  • Novartis Investigative Site

    Louisville, Kentucky, 40217

  • Novartis Investigative Site

    Memphis, Tennessee, 38125

  • Novartis Investigative Site

    Meridian, Idaho, 83642

  • Novartis Investigative Site

    Metairie, Louisiana, 70006

  • Novartis Investigative Site

    Midlothian, Virginia, 23114

  • Novartis Investigative Site

    Mineola, New York, 11501

  • Novartis Investigative Site

    Missoula, Montana, 59804

  • Novartis Investigative Site

    Mobile, Alabama, 36608

  • Novartis Investigative Site

    Mogadore, Ohio, 44260

  • Novartis Investigative Site

    Murrells Inlet, South Carolina, 29576

  • Novartis Investigative Site

    New Hyde Park, New York, 11042

  • Novartis Investigative Site

    Newport News, Virginia, 23606

  • Novartis Investigative Site

    Ninety Six, South Carolina, 29666

  • Novartis Investigative Site

    Norwalk, California, 90650

  • Novartis Investigative Site

    Oklahoma City, Oklahoma, 73109

  • Novartis Investigative Site

    Omaha, Nebraska, 68114

  • Novartis Investigative Site

    Omaha, Nebraska, 68134

  • Novartis Investigative Site

    Orangevale, California, 95662

  • Novartis Investigative Site

    Overland Park, Kansas, 66215

  • Novartis Investigative Site

    Owensboro, Kentucky, 42303

  • Novartis Investigative Site

    Pasadena, California, 91105

  • Novartis Investigative Site

    Phoenix, Arizona, 85013

  • Novartis Investigative Site

    Picayune, Mississippi, 39466

  • Novartis Investigative Site

    Roslyn, New York, 11576

  • Novartis Investigative Site

    Salisbury, North Carolina, 28144

  • Novartis Investigative Site

    Scottsdale, Arizona, 85251

  • Novartis Investigative Site

    Shelby, North Carolina, 28152

  • Novartis Investigative Site

    South Miami, Florida, 33143

  • Novartis Investigative Site

    Topeka, Kansas, 66606

  • Novartis Investigative Site

    Troy, Michigan, 48085

  • Novartis Investigative Site

    Varnville, South Carolina, 29944

  • Novartis Investigative Site

    Westlake Village, California, 91361

  • Novartis Investigative Site

    Wilmington, North Carolina, 28401

Other trials in United States

Hungary10 sites
  • Novartis Investigative Site

    Békéscsaba, H-5600

  • Novartis Investigative Site

    Budapest, 1023

  • Novartis Investigative Site

    Budapest, 1027

  • Novartis Investigative Site

    Debrecen, 4032

  • Novartis Investigative Site

    Eger, 3300

  • Novartis Investigative Site

    Gyula, 5703

  • Novartis Investigative Site

    Kistarcsa, 2143

  • Novartis Investigative Site

    Szikszó, Hungary, 3800

  • Novartis Investigative Site

    Szolnok, 5000

  • Novartis Investigative Site

    Veszprém, H-8200

Other trials in Hungary

Germany9 sites
  • Novartis Investigative Site

    Bad Doberan, 18209

  • Novartis Investigative Site

    Bayreuth, 95445

  • Novartis Investigative Site

    Berlin, 13125

  • Novartis Investigative Site

    Löhne, 32584

  • Novartis Investigative Site

    Magdeburg, 39110

  • Novartis Investigative Site

    Messkirch, 88605

  • Novartis Investigative Site

    Regensburg, 93053

  • Novartis Investigative Site

    Weener, 26826

  • Novartis Investigative Site

    Zwiesel, 94227

Other trials in Germany

Lithuania6 sites
  • Novartis Investigative Site

    Kaunas, LT, 50128

  • Novartis Investigative Site

    Kaunas, LT, 51349

  • Novartis Investigative Site

    Klaipėda, 92288

  • Novartis Investigative Site

    Vilnius, LT, 01117

  • Novartis Investigative Site

    Vilnius, 09020

  • Novartis Investigative Site

    Vilnius, LT-08661

Other trials in Lithuania

Canada5 sites
  • Novartis Investigative Site

    Sainte-Foy, Quebec, G1v 3M7

  • Novartis Investigative Site

    Saskatoon, Saskatchewan, S7K 0H6

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1B 5E8

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1E 2C2

  • Novartis Investigative Site

    Toronto, Ontario, M9W 4L6

Other trials in Canada

About this study

Official title: A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.

Being tested
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Keywords
Gout, arthritis, gout flare, acute gout, gouty, rheumatic disease, uric acid
Medical subject headings
Gout, Arthritis, Rheumatic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Canakinumab pre-filled syringeDrug

    Canakinumab pre-filled syringe

  • Canakinumab lyophilized powderDrug

    Canakinumab lyophilized powder

  • Triamcinolone AcetonideDrug

    Triamcinolone Acetonide

  • PlaceboDrug

    Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide

Study groups in NCT01356602
Study groupRoleWhat they receive
Canakinumab, pre-filled syringes (PFS)ExperimentalPatients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
Receives: Drug: Canakinumab pre-filled syringe; Drug: Placebo
Canakinumab, lyophilizate (LYO)Active comparatorThe patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
Receives: Drug: Canakinumab lyophilized powder; Drug: Placebo
Triamcinolone AcetonideActive comparatorThe patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
Receives: Drug: Triamcinolone Acetonide; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups

    The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.

    Measured: 72 hours post dose

Secondary outcomes (17)
  1. Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups

    The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.

    Measured: 72 hours post dose

  2. Patient's Assessment of Pain Intensity on a 0-100mm VAS

    The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. The LOCF method was used to impute post-dose pain intensity VAS measurements up to 14 days.

    Measured: 14 days

  3. Patient's Assessment of Pain Intensity on a 5-point Likert Scale

    A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Patients scored their pain intensity in the most affected joint of the gout flare on a 5-point Likert scale (none, mild, moderate, severe, extreme). The scores were measured to the nearest millimeter from the left. The LOCF method was used to impute post-dose pain intensity Likert measurements up to 14 days.

    Measured: 72 hours

  4. Number of Patients With at Least One New Gouty Arthritis Flare After Baseline

    Patients met the definition of a new flare if they had: a flare in a joint, which was not a previously affected joint (at baseline or during the study), or a flare in a joint previously affected (at baseline or during the study) after the previous flare in that joint had resolved completely according to the patient's perception. Patients did NOT meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely.

    Measured: 12 weeks

  5. Time to the First New Gouty Arthritis Flare

    Patients met the definition of a new flare if they had: a flare in a joint, which was not a previously affected joint (at baseline or during the study), or a flare in a joint previously affected (at baseline or during the study) after the previous flare in that joint had resolved completely according to the patient's perception. Patients did NOT meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely. Less than 50% of patients had new flares. Therefore, the median time to new flare could not be calculated.

    Measured: 12 weeks

  6. Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS

    The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Kaplan Meier estimate of time to 50% reduction in baseline pain, along with associated 95% confidence interval, were reported.

    Measured: 14 days

  7. Time to Resolution of Gouty Arthritis Flare as Reported by Patient

    Patients completed diary entries at 6, 12, 24, 48 and 72 hours post dose and then daily up to 7 days post-dose and/or daily until resolution of the flare. Kaplan Meier estimate of time to resolution of gouty flare as reported by patient, along with associated 95% confiedence interval, were reported.

    Measured: 14 days

  8. Patient's Global Assessment of Response to Treatment on a 5-point Likert Scale

    A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Patients scored their response to treatment on a 5-point Likert scale (excellent, good, acceptable, slight, poor). This outcome measure shows the number of patients indicating each score on the scale.

    Measured: 72 hours

  9. Physician's Global Assessment of Response to Treatment on a 5 Point Likert Scale

    A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Study physicians scored their assessment of the patients' response to treatment on a 5-point Likert scale (very good, good, fair, poor, very poor).

    Measured: 72 hours

  10. Physician's Assessment of Tenderness

    The study physician assessed the most affected joint for tenderness. Tenderness was measured on a 0 - 3 point scale as follows: 0 = no pain, 1 = patient states that "there is pain", 2 = patient states "there is pain and winces" and 3 = patient states "there is pain, winces and withdraws" on palpation or passive movement of the affected study joint.

    Measured: 72 hours

  11. Physician's Assessment of Swelling

    The study physician assessed the most affected joint for swelling. Swelling was measured on a 0 - 3 point scale as follows: 0 = no swelling, 1 = palpable, 2= visible and 3 = bulging beyond the joint margins.

    Measured: 72 hours

  12. Physician's Assessment of Erythema

    The study physician assessed the most affected joint for erythema. Erythema was assessed as present, absent or not assessable.

    Measured: 72 hours

  13. Physician's Assessment of Range of Motion of the Most Affected Joint

    The study physician assessed the patient's range of motion of the most affected joint on a 5 point Likert scale (normal, mildly restricted, moderately restricted, severely restricted and immobilized).

    Measured: 72 hours

  14. Proportion of Patients With Rescue Medication Intake

    Patients used a diary to record the time of intake of rescue medication and the amount taken.

    Measured: 12 weeks

  15. Time to First Rescue Medication Intake

    Patients used a diary to record the time of intake of rescue medication and the amount taken.

    Measured: 14 days

  16. Amount of Rescue Medication Taken (mg)

    Patients used a diary to record the time of intake of rescue medication and the amount taken.

    Measured: 14 days

  17. C-reactive Protein Level

    A central laboratory was used for analysis of all blood samples collected.

    Measured: 72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2011 (estimated)
  2. Study startMay 2011
  3. Primary completionSep 2012
  4. Study completionSep 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
397 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01356602
Sponsor's protocol ID
CACZ885H2361
Other IDs
2010-024173-39
Status last verified
Dec 2013
First submitted
16 May 2011
Last updated
29 Jan 2014

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide in people with Acute Gouty Arthritis, run by Novartis Pharmaceuticals at 99 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 99 sites in United States, Hungary, Germany, Lithuania, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Jan 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups (time frame: 72 hours post dose). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in